期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 38, 期 11, 页码 992-1005出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2017.08.003
关键词
-
资金
- Russian Science Foundation [14-50-00069]
- Russian Foundation for Basic Research [16-04-00851]
- Southwest University
- ZENEREI Center
- St. Petersburg State University
- Ural Federal University
- Guangdong Ocean University
Psychedelic drugs, such as lysergic acid diethylamide (LSD), mescaline, and psilocybin, exert profound effects on brain and behavior. After decades of difficulties in studying these compounds, psychedelics are again being tested as potential treatments for intractable biomedical disorders. Preclinical research of psychedelics complements human neuroimaging studies and pilot clinical trials, suggesting these compounds as promising treatments for addiction, depression, anxiety, and other conditions. However, many questions regarding the mechanisms of action, safety, and efficacy of psychedelics remain. Here, we summarize recent preclinical and clinical data in this field, discuss their pharmacological mechanisms of action, and outline critical areas for future studies of psychedelic drugs, with the goal of maximizing the potential benefits of translational psychedelic biomedicine to patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据